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ABSTRACT
Purpose Dynamic in-situ proton (1H) magnetic resonance im-
aging (MRI) and 1H T2-relaxometry experiments are de-
scribed in an attempt to: (i) understand the physical processes,
that occur during the reconstitution of lyophilized bovine se-
rum albumin (BSA) andmonoclonal antibody (mAb) proteins;
and (ii) objectify the reconstitution time.
Methods Rapid two-dimensional 1H MRI and diffusion
weighted MRI were used to study the temporal changes
in solids dissolution and characterise water mass trans-
port characteristics. One-shot T2 relaxation time mea-
surements were also acquired in an attempt to quantify
the reconstitution time. Both MRI data and T2-relaxa-
tion data were compared to standard visual observations
currently adopted by industry. The 1H images were fur-
ther referenced to MRI calibration data to give quanti-
tative values of protein concentration and, percentage of
remaining undissolved solids.
Results An algorithmic analysis of the 1H T2-relaxation data
shows it is possible to classify the reconstitution event into
three regimes (undissolved, transitional and dissolved).
Moreover, a combined analysis of the 2D 1H MRI and 1H
T2-relaxation data gives a unique time point that characterises
the onset of a reconstituted protein solution within well-
defined error bars. These values compared favourably with
those from visual observations. Diffusion weighted MRI
showed that low concentration BSA and mAb samples
showed distinct liquid-liquid phase separation attributed to
two liquid layers with significant density differences.
Conclusions T2 relaxation time distributions (whose interpre-
tation is validated from the 2D 1H MR images) provides a
quick and effective framework to build objective, quantitative
descriptors of the reconstitution process that facilitate the in-
terpretation of subjective visual observations currently
adopted as the standard practice industry.
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INTRODUCTION
Lyophilization is a unit operation used extensively in the bio-
pharmaceutical industry aimed at producing dry stable pro-
tein formulations containing 0.1–4%water (with <0.3% often
achieved in modern formulation), thereby increasing the sta-
bility and shelf life of the product (1–5). Prior to patient ad-
ministration, the lyophilized drug product must be
reconstituted. The reconstitution times of such formulations
can vary significantly, from minutes to hours with the longer
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reconstitution times generally observed for high concentration
protein formulations (6–9). Lyophilization is relatively compli-
cated and involves a number of variables, which have long
been considered in the literature using a wealth of analytical
techniques, both from a process performance and product
quality point of view (8–10). However, factors influencing
the reconstitution of lyophilized drug products are still poorly
understood, with the effect of even common steps of the ly-
ophilization process still debated. For example, annealing,
which is often included during freezing to improve the
crystallisation and pore size, has been shown to both
increase (11) and decrease (12,13) reconstitution times.
Reconstitution procedures can vary from one therapeutic
protein product to another, making empirical observations of
reconstitution times subjective and difficult to compare.
Recently, efforts have been made to standardise definitions
such that the reconstitution time is generally recorded after
injection ends until all visible solids have dissolved (14,15),
while amounts of diluent and agitation methods are typically
s ta ted. The United States Pharmacope ia (USP)
Pharmacopeial Forum (16) indicates that to ensure full recon-
stitution there should be no “visible residue” and that “the
constituted solution is not significantly less clear than an equal
volume of the diluent”. It has also given revisions (17) on
guidelines of visual inspection largely based on the work of
Melchore and Berdovich (18). It is recognised by USP that
this is a probabilistic determination and so remains subjective
in nature and dependent on scenario. Werk et al. (19) have
attempted to create an automated method to determine the
endpoint of reconstitution using an impedance based method,
which was shown to be successful so long as temperature and
agitation were controlled. Other techniques used UV (20) and
a laser particle sizer (21) to determine reconstitution endpoint
but were not performed in situ.
Large variations have been observed in reconstitution times
for different products with values as long as 90 min seen in
some snake anti-venoms (22) and anywhere from a few mi-
nutes (or less) (23) to 40 min (15) in the case of some mono-
clonal antibodies. A vast number of product parameters along
with analytical techniques have been investigated and applied
to studying reconstitution after it has occurred and include
particle size distribution and porosity measurements
(15,23–28), lyophilization cooling profile and annealing
(11–13,15,29), diluent volume and vial size (23,29,30), addi-
tives and wetting agents (23,31,32), protein product structure
(23,33,34), reconstitution under vacuum (23) and agitation
(15,23,29). However, to the best of our knowledge there have
been no analytical experimental studies that have been ap-
plied non-invasively to study the real-time reconstitution pro-
cess of a lyophilized product beyond determination of recon-
stitution endpoint (19). Two-dimensional (2D) 1H magnetic
resonance (MR) measurements have, however, been more
widely used to study protein stability and mobility using
relaxation parameters, such as to investigate miscibility with
changing formulations (35), determining sugar types and con-
tent (36), investigating lyophilized systems stored at different
relative humidity (37), and the effect of different polymer ex-
cipients on formulation (38). MR imaging has also been ap-
plied to look at the end point of lyophilization in potatoes (39).
T2 relaxation NMR has recently been used to investigate pro-
tein aggregation using a low field bench top NMR spectrom-
eter. The results were shown to be superior to traditional
methods such as size exclusion chromatography, dynamic
light scattering and micro-flow imaging (40). Solid state
NMR measurements on lyophilized drug products using T1
and T1ρ relaxometry are more common, for example looking
at annealing (41) and protein stability (42,43).
In this paper we report the use of rapid single-shot one-
dimensional (1D) 1H nuclear magnetic resonance (NMR) T2–
relaxation time measurements combined with fast 2D 1H
magnetic resonance imaging (MRI) methods as a non-
invasive tool for monitoring the reconstitution process within
a standard lyophilized sample vial. Single shot magnetic reso-
nance T2-relaxation data (analysed using numerical inversion)
coupled with spatially resolved MRI data allow us to objec-
tively partition the in-situ reconstitution process into three
distinct regimes denoted: (0) undissolved; (1) transitional; (2)
dissolved. The analysis provides two distinct time points asso-
ciated with the onset of steady state morphological behaviour
and a time point where reconstitution can be considered com-
plete within error limits. The MR image data can be calibrat-
ed to external reference samples to provide measures of pro-
tein concentrations and remaining undissolved solids content
after reconstitution for comparison with standard UV analy-
sis. The combination of magnetic resonance imaging and re-
laxation methods are then used to provide a physical interpre-
tation of the reconstitution process.
EXPERIMENTAL
Materials and Lyophilization Methods
Bovine Serum Albumin (BSA) was purchased as dry powder
(product code A4503, Lot #SLBP3628V, MW 66.4 kDa, pI
~4.8, extinction coefficient 0.67 (mg/ml)/cm from Sigma-
Aldrich (Merck), UK. Samples of a recombinant, human
IgG1 monoclonal antibody (hereafter referred to as ‘mAb’),
MW 143 kDa, pI ~9, extinction coefficient 1.41 (mg/ml)/cm,
were prepared by AstraZeneca plc, Cambridge, UK, in
13 mm Schott Type I clear tubular 3 ml glass vials (West
Pharmaceutical Services) and stoppered with Daikyo D777–
1 13 mm single vent lyo-stoppers (West Pharmaceutical
Services). A VirTis Genesis freeze drier was used with an
annealing step included in the cooling profile. After this the
pressure was reduced to 100 mTorr and the temperature
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lowered to −25°C for 55 h for primary drying. The temper-
ature was then ramped at 0.1 °C per minute to 40 °C while
maintaining 100 mTorr pressure for 6 h to allow for second-
ary drying. BSA was dissolved at a target concentration of
150 mg/ml in 240 mM sucrose, 20 mM histidine/histidine
HCl, 0.02% polysorbate 80 (w/v) pH 6.0 (‘BSA buffer’), and
diluted to 20mg/ml over a range of concentrations. ThemAb
was first dialysed (20 kDa MWCO Slide-A-Lyzer™ Dialysis
Cassettes, Thermo Fisher Scientific, UK, following the man-
ufacturer’s instructions) into 80 mM arginine HCl, 120 mM
sucrose, 20 mM histidine/histidine HCl, 0.02% polysorbate
80 (w/v) pH 6.0 (‘mAb buffer’), concentrated to around
150 mg/ml (30 kDaMWCOAmicon Ultra centrifugal filters,
Merck, UK) and diluted to 20 mg/ml over a range of concen-
trations. The concentration of representative samples for each
dilution step was measured in triplicate by UV-absorbance at
280 nm (A280) using a Trinean DropSense Multi-Channel
Spectrophotometer (Unchained Labs Inc.). The effect of for-
mulation and lyophilization process parameters are outside
the scope of this work. For brevity samples will be referred
to by their protein concentration only e.g. BSA with a target
protein concentration of 20 mg/ml will be referred to as BSA
20.
The in situ sample vial holder for use within the
magnet was made of Poly-Ether Ether Ketone and the
setup driven by a computer controlled Harvard
Instruments Model 22 syringe pump. A reconstitution
volume of 1 ml of 15 MΩcm deionised water was used
for all samples bringing them back to their original
concentrations. A flow rate of 5 ml/min was used (i.e.
injection duration was 12 s). A schematic of the sample
vial holder is shown in Fig. 1.
Magnetic Resonance Methods and Data Analysis Procedures
All magnetic resonance experiments were conducted on a
Bruker Biospin Ultrashield 9.4 T (400 MHz 1H frequency)
widebore magnet combined with a Bruker Biospin Avance
spectrometer, using a 25 mm micro-imaging probe. One shot
T2 data were acquired using a standard Carr-Purcell-
MeiboomGill (CPMG), pulse sequence; the interecho spacing
was 5 ms and a total of 512 echoes were acquired. The
oneshot T2 data were acquired every 12.2 s up to a total time
of t = 1565 s and 3620 s for BSA and mAb samples respec-
tively. The data was analysed using a one dimensional numer-
ical inversion, sometime referred to as an Inverse Laplace
Transform (ILT), as described in the literature (44–52). The
Laplace inversion was adopted here because it is a general and
robust method that is used when no prior information about
the number and distribution of T2 values is known. At the end
of each experiment the sample was removed from the magnet,
swirled gently for 1 min by hand and then replaced back into
the magnet and three further one shot experiments were
acquired and subsequently transformed using numerical in-
version to obtain a T2 data set representative of time t =∞
(tinf). Three repeats (n= 3) were performed for all samples.
T2 Partitioning
Following numerical inversion of each in situ one-shot T2 ex-
periment the resulting relaxation time distributions are
partitioned according to the following procedure:
(i) A weighted average ‘reference’ T2 value (tref), of a pure
buffer solution, i.e. without BSA or mAb, is calculated for
the first time point of the reconstitution process at t = 0 s
(Fig. 2(a)). The weighted average of a T2 distribution is
calculated by multiplying each fractional probability value
by its corresponding T2 relaxation time and then summing
those values. This sum is then divided by the sum of the
fractional probabilities to give the weighted average.
Fig. 1 Schematic of the in situ injection setup.
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Fig. 2 (a) T2 distribution obtained at time zero for the BSA buffer solution. Solid vertical line represents tref, the weighted average T2 value for BSA buffer at t =
0 s. (b) T2 distribution for BSA 150 taken at t = 722 s, the solid vertical line represents tav, the weighted averaged T2 value. (c) T2 distribution from BSA 150
extracted after swirling the sample. Solid line represents the weighted average T2 value at t =∞ (tinf). Dashed line represents tinf + 3σ. (d) Schematic 1D color
map that evolves with time from the assignment of the 3 integer values following the partitioning criteria (i-vi) listed in the “T2 Partitioning” section. Note the sharp
transitions from black to red and red to yellow represent an average weighted T2 value from three independent samples (n =3).
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(ii) A weighted average T2 value (tav) of each individual T2
distribution for BSA andmAb samples is calculated for all
individual time points during the reconstitution (Fig. 2(b)).
(iii) A weighted average T2 value of swirled samples, to give a
single T2 relaxation value at t =∞, is calculated and
denoted tinf (Fig. 2(c)).
(iv) If the weighted average, tav is greater than tref, then those
values are assigned an arbitrary value of 0 and corre-
spond to samples with undissolved large bulk solids; time
points where this condition is true are subsequently re-
ferred to as “undissolved”.
(v) If tinf + 3σ< tav < tref, then the T2 values are given an
arbitrary value of 1 and are representative of a system
that is “transitional” (see Fig. 2(b)).
(vi) The remaining T2 values i.e. those with tav < tinf + 3σ are
considered to represent a system that has fully dissolved,
and are assigned an arbitrary value of 2 (see Fig. 2(c,d))
and denoted “dissolved”
This procedure when applied to the weighted T2 re-
laxation distributions, results in 1D color maps of a
particular sample with three values representing undis-
solved (0 = black), transitional (1 = red), and dissolved
(2 = yellow) during the time evolution of the reconstitu-
tion process. An example of this T2 partitioning is
shown in Fig. 2(d). Error bars in the T2 relaxation data
are calculated from three separate reconstitution exper-
iments. We note that the width of the T2 distribution
arises from the regularisation procedure that is used in
conjunction with the numerical inversion (44–54).
MR Imaging
For 2D 1H MRI measurements, a single shot Rapid
Acquisition with Relaxation Enhancement (RARE) sequence
was used for reconstitution experiments with a rare factor of
128 and an inter-echo echo time of 2.5 ms giving an effective
T2 weighting of the
1H signal from water of 160 ms. A recycle
time of 8 s was used for all imaging to allow >95% (~3 ×T1)
of the 1H signal from water to relax back to equilibrium fol-
lowing excitation. 2D images in the ZX plane were recorded
using 128 (Z) × 64 (X) pixels with a spatial resolution of 125 ×
250 μm. The slice thickness was 16 mm meaning the images
are a projection of the entire y-axis onto a 2D plane. In order
to capture the dynamics of the reconstitution process 2D 1H
RARE images were acquired every 8 s so that T1-relaxation
contrast was negligible and only T2-contrast needed to be
accounted for. Up to 200 1H 2DRARE images were acquired
in a typical reconstitution run resulting in a total imaging time
of 26 min. After 26 min, the sample was physically removed
from the magnet, swirled for 2 min by hand, and then placed
back in the magnet for six final shot XY and ZX RARE
images giving an image at t =∞. For mAbs, 440 1H 2D
RARE images were recorded (~1 h), before the sample was
removed and swirled, while mAb 125 and 150 samples had to
be set aside for longer to allow full reconstitution. Three re-
peat experiments were performed for both BSA and mAb. All
MR images were processed off-line using Matlab™.
Diffusion Weighted Imaging
A pulse gradient spin echo (PGSE) diffusion weighted imaging
RARE sequence (55) was used to obtain spatially resolved
maps of the molecular self-diffusion coefficient of the water
in certain samples. All the 1H RARE imaging parameters in
the PGSE weighted RARE sequence were identical to those
used for standard RARE imaging described above. The
PGSE parameters were as follows; 8 increments of the diffu-
sion gradient, g, ranging from 0.1 T m−1 to 1.0 T m−1, δ=
3.0 ms, Δ= 8.0 ms, number of scans = 4. Each pixel in the
series of eight diffusion weighted images were fitted to the
standard Stejskal-Tanner equation in Matlab with a single
fitting parameter giving the self-diffusion coefficient D of the
water in m2 s−1.
Protein Concentration Calibration Procedure Using MRI
In order to convert the t =∞ 1H intensity images into protein
concentration images, a calibration procedure was developed
and is briefly described below with additional material in the
supplementary information S1-S3.
(1) Following in situ measurement, the vial is removed from
the magnet and swirled until all solids were dissolved.
(2) Serial dilutions were prepared at six concentrations from
the swirled vials, starting with no dilution.
(3) The samples were then transferred from the reconstituted
vials into standard 5 mm NMR tubes
(4) Up to seven 5 mm NMR tubes were placed in a
holder (6 sample concentrations and water) and
then into the MRI magnet. A single shot 1 mm
slice selective RARE XY image was taken with
the same echo-time (TE = 2.5 ms) and RARE factor
(128) as that used for the ZX reconstitution imag-
ing. This procedure ensures exactly the same T2
weighting (contrast) is applied to the calibration
phantom of 5 mm NMR tubes to that of the vials
during the actual reconstitution experiments.
Example images for all BSA and mAb samples
can be seen in Figure S1.
(5) Following Fourier transformation of the raw calibration
image data, a 3 pixel grid of points was taken from the
centre of each individual 5 mmphantom and averaged to
give a single value at each individual serial dilution. The
data from such analysis are plotted in Figure S2 and show
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an exponential decrease in 1H signal intensity for all
phantoms and serial dilutions.
(6) Three fitting parameters are determined for each individ-
ual BSA andmAb concentration. Each fitting parameter is
then individually plotted against the protein concentration
determined byUV analysis thus yielding a general formula
or master curve for each fit parameter. This general for-
mula can then be used to calculate the “NMR” reconsti-
tution protein concentration value, Figure S3.
(7) Protein concentration images/maps are corrected for the
cylindrical projection geometry by dividing each map by
one obtained from pure water.
RESULTS & DISCUSSION
Lyophilized Product Appearance
Figure 3 shows the appearance of lyophilized BSA and mAb
samples, as well as their respective lyophilized buffers. Product
shrinkage increases with protein concentration for both BSA
and mAb, with cracking observed in BSA 125 and BSA 150,
Fig. 3(c), and very minor cracking in the mAb 150 prepara-
tion, Fig. 3(f). In addition, Fig. 3 also shows solids attached to
the inner rim of the vial for all samples.
Protein Concentrations and Visual Reconstitution Times
To ensure comparability of visual data available in the sup-
plementary information S5, S7 with that of MRI data, no
agitation of any sort was applied. Reconstitution times based
on visual observation are summarized in Table I. The recon-
stitution time was taken from the end of injection until no
visible solid particulate matter was observable. This is noted
to cause a considerable sample to sample variation at all con-
centrations due to persistent solid particles in some instances.
In the case of higher concentration mAb samples
(≥100 mg/ml) the times are inflated by tiny solid residue ad-
hered to the inner vertical walls of the glass vials. The recon-
stitution times for both BSA and mAb samples were generally
found to increase with protein concentration, with much lon-
ger reconstitution times evident for higher concentrations
(≥100 mg/ml), particularly in the case of the mAb samples.
Magnetic Resonance Studies of the Reconstitution
Process
The following sections first focus on the interpretation of the in
situ 2D 1H MRI data; this is followed by a description and
discussion of the T2 relaxation distributions and their
Fig. 3 Appearance of lyophilized: (a) BSA buffer, (b) BSA 20, (c) BSA 150, (d) mAb buffer, (e) mAb 20, and (f) mAb 150. See Table I for actual protein
concentrations. Z axis is in the direction of the vial vertical.
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subsequent partitioning analysis. Finally, a discussion combin-
ing both imaging and relaxation data is presented to under-
stand the physical interpretation of the T2 relaxation time
distributions.
MRI of Lyophilized Product Reconstitution
BSA and mAb 20 mg/ml Samples. Figure 4(a-c) shows 1H mag-
netic resonance images for BSA 20 at three different times
during the reconstitution process, (the complete set of images
are available as supplementary data S4). At t = 60 s post ad-
dition of 1 ml of water, two distinct regions of different 1H
signal intensity are evident: (i) a large upper region of high 1H
signal intensity (yellow) covering most of the visible image and
(ii) a much smaller region at the bottom of the vial with lower
overall 1H signal intensity (blue green). Region (i) is indicative
of water with a small amount of dissolved solids present where-
as region (ii) contains a very high amount of dissolved solids.
The reason for the low 1H signal intensity towards the bottom
of the sample vial in the image is due to the T2 relaxation
contrast introduced into the image by the RAREMR imaging
sequence (55). It is worth noting again that the images are a
projection of the entire y-axis onto a 2D plane, thus given the
cylindrical vial geometry the intensity is expected to be greater
in the middle of the vial where a greater volume of 1H spins
are present. In general, the lower the actual T2 value of a
1H
spin system the less signal will be present in the images. The
reason for the region of low 1H intensity may be explained by
inspection of the visual reconstitution images (see supplemen-
tary data S5) which show a rapid breakdown of the lyophilized
product and subsequent fall in vertical height as the first drops
of liquid water hit the top surface of the product. Rapid
dissolution causes a liquid region with higher dissolved solids
at the bottom of the vial. Subsequent drops of water then
collect on top of this region and this water has much less
dissolved solids resulting in a high 1H signal intensity given
by the yellow color in Fig. 4(a,b). At t = 720 s the MR images
show that the lower 1H signal intensity region has propagated
upwards at the expense of the higher 1H intensity region
above it, with approximately 1/3 of the sample area now
having a lower 1H signal intensity; this is a result of Fickian
diffusive mixing driven by solute concentration differences
and is verified in a later section. A comparison of the MRI
data at t = 720 s with visible observations at an equivalent
time shows that there are no visible solids present in the bulk
liquid at t = 720 s. Following mechanical swirling and replace-
ment of this sample back into theMR scanner a homogeneous
distribution of 1H signal intensity is restored across the image
at t =∞. Figure 5(a-c) shows a qualitatively similar behavior
for mAb 20 with distinct stratification being observed at t = 60
and 720 s along with a homogenous 1H signal intensity distri-
bution post swirling at t =∞.
BSA 50–100 mg/ml Samples. Figure 4(d-l) shows the 1H images
obtained during the reconstitution process for BSA 50, 75 and
100 samples. Again, at t = 60 s, all three sample concentra-
tions display two vertical regions of higher and lower 1H signal
intensity. The increase in 1H signal intensity for BSA 100
relative to BSA 75 is indicative of different spatial concentra-
tions of dissolved solids, with BSA 100 maintaining less dis-
solved solid upon initial hydration. At t = 720 s two stratified
regions are visible but are considerably less discernible than
for BSA 20. A homogenous distribution in 1H signal intensity
is observed post swirling at t =∞.
Table I Measured Weighted
Mean Protein Concentration
Determined by UVAbsorbance and
Visual Reconstitution Times for n
Sample Preparations
Formulation Weighted Mean Concentration± SD
(mg/ml)
n Reconstitution Time± SD
(s)
n
BSA buffer – – 70± 20 3
BSA 20 20± 2 11 90± 20 3
BSA 50 51± 2 8 140± 50 3
BSA 75 79± 3 12 220± 60 3
BSA 100 104± 4 8 260± 40 3
BSA 125 124± 3 11 1300± 100 3
BSA 150 159± 8 10 2100± 100 3
mAb buffer – – 40± 20 3
mAb 20 19± 2 10 130± 30 3
mAb 50 49± 2 8 260± 40 3
mAb 75 75± 1 10 600± 100 3
mAb 100 105± 1 8 3000± 900* 3
mAb 125 128± 9 10 6500± 400* 3
mAb 150 153± 4 10 10,000± 1000* 3
*mAb reconstitution times significantly longer due to product sticking to the inner rim of the glass vials
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Fig 4 1HMRI images at t = 60 s, 720 s and post swirling (t =∞) respectively for: (a) - (c) BSA 20, (d) - (f) BSA 50, (g) - (i) BSA 75, (j) - (l) BSA 100, (m) - (o) BSA
125 and (p) - (r) BSA 150.
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mAb 50–100 mg/ml Samples. Figure 5(d-l) shows the 1H
images obtained during the reconstitution process for
mAb 50, 75 and 100 samples. At t = 60 s, both mAb 50
and 75 show a homogenously distributed 1H signal, indic-
ative of evenly dispersed undissolved solids in a liquid
layer. A subtle feature of Fig. 5(d, g) is that the height of
the meniscus is significantly reduced when compared to
the sample(s) images at t = ∞ (Fig. 5(f, i)). The reason for
this is due to the early formation of a liquid/air foam
layer that resides on top of the main bulk liquid (this is
also supported by the visual observations given in the
supplementary information S5). This foam layer is invisi-
ble to the RARE MRI sequence due to foam having a
short T2 value; however as the liquid phase of the foam
drains into the main bulk liquid below, the height of the
meniscus gradually increases. For mAb 100 at t = 60 s, the
bulk signal in the image is similar to mAb 50 and 75 but
faint 1H intensity shown by dark blue colors above the
bulk liquid is indicative of a partially wetted large solid
mass. At t = 720 s, there is some evidence of 1H intensity
inhomogeneity near the corners of the vial in mAb 50 and
75. These samples are in general much more homogenous
than their BSA 50 and 75 counterparts. At t = 720 s, mAb
100 shows higher 1H intensities when compared to mAb
50 and 75 due to regions of undissolved solid material
residing in the bulk liquid. All samples conform to a ho-
mogeneous solution after swirling at t =∞.
BSA 125–150 and mAb 100–150 mg/ml Samples. Figure 4(m-r)
shows the 2D 1H MR imaging results for BSA 125 and 150
while Fig. 5(m-r) shows those for mAb 125 and 150. At t =
60 s, all samples show a high 1H signal intensity region at the
top of the vial consistent with free water, as well as a region of
little to zero signal intensity (white areas) representing undis-
solved, undisturbed solid product. Small amounts of water
penetration down the sides are evident, particularly in the case
of BSA 125.
At t = 720 s, a near homogeneous distribution in 1H
signal intensity is observed for BSA 125 while BSA 150
shows evidence of partial reconstitution (i.e. undissolved
solids mixed in a partially reconstituted solution). At t =
720 s, mAb 125 begins to homogenize in physical height
but the more intense, less homogeneous 1H signal is in-
dicative of large undissolved solid regions within the main
liquid bolus. For mAb 150 at t = 720 s, an intense 1H
signal (yellow color) with a curved meniscus above is also
seen; this is indicative of pure water that has penetrated
around the sides of the vial and, as it does so, it pushes the
solid product vertically upwards so that the undissolved
solid mass effectively floats on the liquid below; again
these observations are supported by visual observations
(supplementary information S5). All samples conform to
a homogeneous solution after swirling at t =∞.
Determining the Morphological Steady State of Reconstitution
For all BSA and mAb samples it is important to deter-
mine when a reconstituting system has physically
reached a morphological steady state following the ad-
dition of 1 ml of reconstituting liquid. We define the
morphological steady state as one in which there are no
distortions to the physical shape of the 2D images. In
an attempt to determine this steady state condition ob-
jectively we analyze, morphologically, the temporal
changes in the physical shape of the 1H MR images
for each individual sample shown in Figs. 4 and 5 ac-
cording to the procedure outlined below:
(1) All 1H images are first thresholded with a single
value to produce a binary image containing only
ones and zeros.
(2) The binary images are then projected along the x-axis to
give a single value for each individual image versus time.
(3) The average value of the last ten images is then taken as a
steady state reference value.
(4) All numerical values of the previous images are
then compared to the steady state value and when
the difference is within ±3 units then the system is
deemed to have reached steady state.
Figure 6 shows the result of this analysis for all BSA and
mAb samples and the numerical values extracted from Fig. 6
are shown in Table II. Fig. 6 and Table II generally show that
the steady state time increases with increasing protein concen-
tration in line with the visual observations (see supplementary
information S5).
The physical interpretation of the results following the
morphological analysis of the images is subtle. As no more
water enters the system after injection at the start of the ex-
periment, any increase or decrease outside the error boundary
(3 units) relative to the reference value is attributed to the
physical movement of large clumps of solids and/or foam
within the system. These physically displace the liquid to dif-
ferent spatial positions within the field of view of the image.
Larger errors in Table II are generally seen for higher con-
centration samples indicating the movement of large lumps of
solids or foam drainage. In general, the reproducibility for
BSA samples is good for lower concentration samples but for
BSA 125 and 150 a larger error is observed, due to bulk
solids/foam movement. The subsequent dissolution behavior
for BSA 125 and 150 samples will likely depend upon the
sample-to-sample variation in micro cracks present in the ini-
tial dry solid product as shown in Fig. 3(c). Further interpre-
tation and consequences of the data presented in Table II and
Fig. 6 are presented in “Partitioning of the T2 Relaxation
Distributions” section where the T2 partitioning analysis of
the T2 relaxation time distributions are discussed.
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Fig. 5 1H MRI images at 60 s, 720 s and post swirling (t =∞) respectively for: (a) - (c) mAb 20, (d) - (f) mAb 50, (g) - (i) mAb 75, (j) - (l) mAb 100, (m) - (o)
mAb 125 and (p) - (r) mAb 150.
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Self-Diffusion Maps from MR Images
In order to investigate the mass transport characteristics
of stratified systems discussed in the previous section,
diffusion weighted MRI RARE imaging was performed
(55). Fig. 7(a) shows a water self-diffusion coefficient map
of a BSA 20 sample at t = 720 s and Fig. 7(b) shows a
self-diffusion coefficient map for the same sample after
swirling. Fig. 7(a) shows two distinct regions, a yellow
upper and a blue/green lower, with average self-
diffusion coefficients corresponding to 1.2 ± 0.1 ×
10−9 m2 s−1 and 0.5 ± 0.1 × 10−9 m2 s−1 respectively.
Hence the stratification phenomena observed are due
to differences in fluid density causing a difference in wa-
ter mobility, with the lower layer in the images for BSA
20 being considerably more viscous than the upper layer.
The reduced mobility of the water results in a lower T2
relaxation time value as the intensity of the 1H signal
acquired using the RARE imaging sequence is propor-
tional to T2 relaxation, with lower relaxation times giv-
ing less signal. Fig. 7(b) shows the water self-diffusion
map after physical agitation (swirling) of the same sample
and clearly shows a more uniform behaviour correspond-
ing to a homogeneously mixed solution of dissolved pro-
tein, with an average diffusion coefficient of 1.0 ± 0.1 ×
10−9 m2 s−1. A similar interpretation can also be applied
to mAb 20 shown in Fig. 7(c) and (d). The average dif-
fusion coefficients of the top and bottom layers in Fig.
7(c) are 1.4 ± 0.1 × 10−9 m2 s−1 and 0.6 ± 0.1 ×
10−9 m2 s−1 respectively, while the swirled value average
for Fig. 7(d) is 0.87 ± 0.03 × 10−9 m2 s−1. For reference,
the diffusion constants for BSA and mAb buffer alone
were measured at 1.0 ± 0.1 × 10−9 m2 s−1 and 0.86 ±
0.05 × 10−9 m2 s−1. It is important to point out that
when BSA and mAb 20 samples were left in the magnet
and continuously imaged over 14 h without removal (and
hence no mechanical agitation/swirling) they do produce
a homogeneously mixed solution due to diffusive mixing
over a long timescale (see supplementary data S6).
T2 Relaxation Time Distribution Data
In order to complement and enhance the observations
from the 1H 2D imaging data one-shot T2 CPMG relax-
ation time data were acquired for all samples discussed
so far. The numerical inversion analysis of the one shot
T2 relaxation time decays results in a time resolved prob-
ability density plot of relaxation time distributions. Fig. 8
shows the complete evolution of normalised T2 relaxa-
tion time distributions for all BSA samples after addition
of 1 ml of water. The horizontal axis in these plots gives
the reconstitution time, the vertical axis denotes the ac-
tual T2 relaxation time parameter obtained from the
numerical inversion analysis; the color scale bar to the
right of each plot represents the probability of each par-
ticular relaxation time. Table III shows the weighted tav
values extracted from both BSA and mAb sample T2
distributions at three different time points. In general,
BSA samples have final T2 values which vary from 50
to 30 ms, while mAb samples have a tighter range of 49
to 36 ms, as concentration increases from 20 to
150 mg/ml. Considering some general features of the
T2 shown in Fig. 8, for BSA 20 a distinct two component
behaviour in the T2-distribution is seen (Fig. 8(a)) and is
attributed to the stratified layers revealed by the 1H im-
ages shown earlier in Fig. 4.
Fig. 6 Results from the morphological analysis procedure outlined in (1–6) above for (a) BSA and (b) mAb images. Grey colors represent times where the
morphology of the image has not reached steady state (unstable) and the light blue regions indicate steady state with the average onset of steady state time defined
by the dark blue lines. Errors are given as a standard deviation for n=3 samples.
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For BSA 50–100 samples (Fig. 8(b-d)) the T2 distributions
quickly approach the tinf value of the swirled solution denoted
on the figure by the white dotted line. For BSA 125 and 150
samples (Fig. 8(e,f)), a distinct chaotic/turbulent behaviour of
the T2 values for 0 < t < 350 s is evident and is attributed to
bulk movement of liquid and solids, which is corroborated by
both the 1HMR images and visual observations for equivalent
samples.
Figure 9 shows the equivalent T2 relaxation time dis-
tributions for mAb samples for t = 0 to t =∞. Similar
features to the BSA samples are observed: for mAb
20 at early times a two component behaviour is seen
indicating distinct stratification (see Fig. 5(a,b)). T2 re-
laxation time distributions for mAb 50, 75 and 100
samples rapidly approach the swirled value of tinf.
Chaotic/turbulent regimes are also seen in mAb 125
and 150 samples for t ~ 30–250 s. Note that for mAb
samples the rate of change of the T2 relaxation time
with reconstitution time decreases with increasing pro-
tein concentration.
Fig. 7 Molecular self-diffusion coefficient 1H images of BSA 20 at (a) t = 720 s and (b) t =∞, and mAb 20 at (c) t = 720 s and (d) t =∞.
Table II Time Points for the
Morphology of BSA and mAb
Sample Images to Reach Steady
State (n=3)
Target Sample Concentration (mg/ml) BSA steady state time± SD
(s)
mAb steady state time± SD
(s)
20 64± 44 96± 72
50 77± 28 266± 128
75 61± 20 408± 30
100 82± 16 1312± 464
125 498± 76 1645± 964
150 973± 297 2347± 549
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Partitioning of the T2 Relaxation Distributions
In an attempt to automate/objectify the analysis procedure to
determine reconstitution time from T2 data, the T2 relaxation
time distributions shown in Figs. 8 and 9 were analyzed ac-
cording to the partitioning conditions outlined in “T2
Partitioning” section. Fig. 10 shows the results of this analysis.
In addition, the data from Fig. 6 are also included in Fig. 10
(as white vertical bars) and show the time when the morphol-
ogy of the liquid in the 1H MR images has reached steady
state. Some general features for the interpretation of Fig. 10
are as follows:
(1) Black colored regions signify an average T2 value that is
greater than the buffer solution reference (condition (iv)
in “T2 Partitioning” section: tav > tref) and are indicative
of solutions with a limited amount of dissolved solid
material and/or large clumps of undissolved solids.
Hence, black regions are referred to as undissolved systems.
The error in the boundaries from black to red are not
included on Fig. 10 but may be found in Table S1 of
supplementary information.
(2) The position of the white vertical bar (and their associat-
ed error boundaries) indicates the time point when the
morphology of the reconstituting system has reached
steady state (data from Table II).
(3) Red colored regions in Fig. 10 correspond to a
system where the weighted average T2 values are
transitioning (condition (v) in “T2 Partitioning” sec-
tion: tinf + 3σ < tav < tref) and represents a system
where solids are continuously dissolving into the
bulk liquid or are indicative of fully dissolved
liquid-liquid stratified systems. This region is re-
ferred to as transitional.
Fig. 8 T2 probability distributions (normalised to the swirled data at tinf) from numerical inversion analysis of one-shot CPMG for t = 0 s to t = 1541 s, and post
removal from the magnet followed by swirling and replacement back into the magnet to determine t =∞ (demarcated by the red dashed line): (a) BSA 20, (b)
BSA 50, (c) BSA 75, (d) BSA 100, (e) BSA 125, and (f) BSA 150. The white dashed line indicates the value of tref and the white dotted lines indicate the value for tinf.
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(4) Yellow colored regions in Fig. 10 correspond to condition
(vi) in “T2 Partitioning” section, i.e. tav < tinf + 3σ. The
black hatched vertical bar indicates the time point where
this occurs and is defined as the point where the recon-
stitution can be considered homogeneous and complete
within the sample to sample error (n= 3). Yellow regions
are defined as dissolved.
Two further points are worth noting in relation to (1) and
(2) above. The total time of the reconstitution experiment for
both BSA and mAb samples shown in Fig. 10 is 26 min and
60 min respectively. Visual observations (see also Table I) of
reconstituting reference buffer solutions of both BSA and
mAb, show that these samples are fully reconstituted before
t < 90 s (allowing for error) as shown in Fig. 11. This time
point can thus be used as a control/reference to compare with
the protein containing samples. Hence, the T2-relaxation data
of the buffer samples can be used to refine the reconstitution
time.
Returning to Fig. 10, BSA and mAb samples that have
reached a morphological steady state (white vertical bars,
Fig. 10) by t ~ 240 s and are followed by (or within) red
colored regions are generally deemed transitional, e.g. BSA
20, 50, 75 and 100, and mAb 20 and 50 samples. The figure
of t = 240 s is determined from the visual reconstitution data
for protein samples which for BSA 20, 50, 75 and 100, and
mAb 20 and 50 samples (see supplementary data S5, S7)
shows that there are no visible solids in the bulk solutions by
t = 240 s; these would then be characterized as being fully
reconstituted (fully dissolved) from a visual determination.
The fact that these solutions are deemed (from T2
partitioning), as transitioning, is, in most part, a result of
liquid-liquid stratification from two fluid layers with different
densities with distinct (bi-modal) T2 values, which causes the
weighted average T2 to be higher than that expected for a
homogenous system. As time proceeds the stratified layers
slowly mix and eventually give a homogenous solution with
a mono-modal, symmetric, T2 relaxation time distribution
(see supplementary data S6). Samples that are deemed
transitioning from T2 partitioning alone and have also reached
a morphological steady state by t ≤ 240 s are subject to an
additional analysis, called differential T2 analysis, that allows
a more definitive reconstitution time to be determined. Once
this time is calculated, these samples can be considered as fully
dissolved. The differential T2 analysis is described as follows:
(1) The tav data extracted from Figs. 8 and 9 may be differ-
entiated, dtavdt
 
, with respect to time to obtain plots show-
ing how dtavdt
 
varies with reconstitution time (see Fig. 12).
(2) The dtavdt
 
values for the buffer solution are also calculated
and plotted
(3) An average value dtavdt
 
and standard deviation (σ) for the
reference buffer solution(s) is then calculated between two
time limits: (i) a lower t = 90 s limit determined from
visual observations of reference buffer samples and (ii)
an upper limit of t = 240 s corresponding to the time
the visual reconstitutions for protein containing samples
are deemed complete (see supplementary Figure S7).




data from the protein samples in (1) up to t =
300 s and when those values are greater than or equal
to dtavdt −3σ
 
for the reference buffer solution, then the
corresponding time point along the horizontal axis is not-
ed and assigned the time for reconstitution.
The results of this T2 differential analysis are shown in
Fig. 12 and the reconstitution times are given in Table IV. A
reasonable agreement for BSA samples (given the errors asso-
ciated with both visual and MRI determined reconstitution
times) is evident with a closer agreement for mAb samples.
For BSA samples it is evident that dtavdt
 
for BSA 20 is the
slowest to approach dtavdt −3σ
 
of the reference buffer samples,
taking around 159 s and BSA 100 is the quickest to approach
the buffer reference yielding a reconstitution time 69 s. The
reconstitution time resulting from the T2 differential analysis
for BSA 20 is somewhat longer than the visual reconstitution
time but is within the error associated with the differential T2
analysis. It is likely that the observed stratification and hence
skewness of the bi-modal T2 distribution still has some impact
in this case. For BSA concentrations of 50–100 mg/ml the
Table III Weighted Average T2 Values from BSA and mAb Samples in
Figs. 8 and 9 Respectively (n=3)







BSA buffer 120± 10 100± 10 51± 1
BSA 20 120± 10 85± 9 50± 1
BSA 50 71± 1 55± 1 47± 1
BSA 75 50± 2 44± 2 38± 1
BSA 100 44± 2 37± 1 34± 1
BSA 125 470± 50 36± 1 34± 1
BSA 150 760± 70 37± 4 30± 1
mAb buffer 110± 10 100± 10 60± 1
mAb 20 90± 10 74± 7 49± 1
mAb 50 91± 4 52± 2 48± 1
mAb 75 140± 20 48± 1 45± 1
mAb 100 600± 200 68± 3 39± 1
mAb 125 1200± 100 65± 3 36± 1
mAb 150 1300± 500* 248± 8* 36± 2
* for mAb 150 at t = 60 and 720 s, n=2 due to limited samples
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reconstitution times determined using the T2 data are gener-
ally shorter than those recorded visually, especially for BSA
100. Despite this, it is suggested that the differential T2 anal-
ysis represents a more objective reconstitution time as it is less
influenced by very small amounts of undissolved solid particles
suspended in the meniscus foam or particles that are stuck to
the edge of the vial that, subjectively, may be deemed impor-
tant or unimportant by an operator. Examples of these obser-
vations can be seen in the visual reconstitution videos (see
supplementary information S5) where occasionally a small
amount of solid material results in a much longer (subjective)
visual reconstitution time, while having limited effect on the
average T2. This is further supported by the reduced standard
deviations in the MRI data compared to the visual observa-
tion data.
Of particular interest is the physical interpretation of the
collective analysis from the different types of magnetic reso-
nance data and subsequent analysis presented here, i.e. steady
state morphological analysis, T2 partitioning, and differential
T2 analysis. For example, consider again the BSA 100 sample
in Fig. 10(a): the white vertical bar determined from morpho-
logical image analysis is located at t = 82 s (see Fig. 6(a) and
Table II) and this time is below the upper, fully reconstituted,
limit of 240 s pre-defined by the visual observations of the
reconstitution process. As the white vertical bar in Fig. 10(a)
is below the 240 s limit a differential analysis of the average T2
is permitted to refine the estimate of the reconstitution time.
An estimate of the value of the reconstitution time from T2
partitioning alone is given at the interface of the red and
yellow regions if such a region is present in the data, i.e. a
system that changes from transitioning to a dissolved system; for
BSA 100 this occurs around t ~ 16 min (960 ± 510 s), which is
clearly well above both the differential T2 analysis and visual
reconstitution times given in Table IV. Hence, the differential
analysis, where appropriate, of the T2 data yields a more
realistic figure (relative to the visual reconstitution times) for
Fig. 9 T2 probability distributions (normalised to the swirled data at tinf) from numerical inversion analysis of one shot CPMG for t = 0 s to t = 3620 s, and post
removal from the magnet followed by swirling and replacement back into the magnet to determine t =∞ (demarcated by the red dashed line): (a) mAb 20, (b)
mAb 50, (c) mAb 75, (d) mAb 100, (e) mAb 125, and (f) mAb 150. The white dashed line indicates the value of tref and the white dotted lines indicated the value
for tinf.
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the reconstitution time, which is reasonable given the errors
associated with both measurements evident in Table IV. The
differential analysis of tav described above is not valid when the
position of the steady state white vertical line in Fig. 10 is
greater than the upper t = 240 s limit determined from the
visual observations, e.g. BSA 125–150 and mAb 75–150
Fig. 11 Visual image of three buffer vials from the same batch at t = 90 s after injection for (a) BSA and (b) mAb.
Fig. 10 Schematic 1Dmaps based upon the partitioning protocol for (a) BSA samples and (b) mAb samples. Three values for the scale bar are used representing
undissolved (black), transitional (red), and dissolved (yellow) time points during the reconstitution process (see “T2 Partitioning” section). The white vertical lines
represent the point at which the morphology of the liquid image has reached steady state and the black hatched bar indicates the time point at which the
reconstitution is deemed complete.
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samples. In these cases, a definitive reconstitution time is only
determinable when the solution has reached a dissolved state as
indicated by the position of the black hatched bar in Fig. 10.
The mAb 125 and 150 samples are not deemed to have
reconstituted by T2/MRI methods at t = 60 min respectively.
Note: if appropriate, the T2-differential analysis takes prece-
dence over T2-partitioning for the assignment of a final recon-
stitution time.
Quantifying Protein Concentrations with MRI
Magnetic resonance imaging is a quantitative technique in
that the amount of signal from a 1H spin system is directly
proportional to the number of 1H nuclei present as long as
both T1 and T2 relaxation contrast in the system are
accounted for (56). The 1H signal in all experiments presented
here is dominated by water as it is in vast excess in terms of
concentration and hence the signal from the protein 1H reso-
nances give a negligible contribution in the 1H RARE images
and corresponding T2 relaxation data. T1 relaxation contrast
for the images shown here can be neglected because the recy-
cle time of the experiment was chosen to ensure that >95% of
the available 1H signal is recovered before subsequent excita-
tion. T2 relaxation time contrast can be accounted for if the T2
relaxation times of each individual pixel is known, however,
this is a time consuming measurement. In order to relate the
1H image water pixel intensity at t =∞ to the dissolved protein
concentration, a calibration method (see experimental section
and supplementary information S1-S3) was developed to al-
low the final protein concentration maps to be determined for
the images at t =∞. Figure 13 shows an example protein con-
centration map at t = ∞ calculated using the procedure
outlined in “Protein Concentration Calibration Procedure
using MRI” section along with a histogram of concentration
values determined by MRI. Table V summarises the results
from final swirled concentration measurements for all samples
and those independently evaluated from exactly the same
samples using the A280 peak in UV absorbance spectroscopy.
The MRI concentration calibration method can also be
used to assess the undissolved solids content for homogeneous
samples that have reached steady state. Here we assume that
Fig. 12 Plots of dtavdt
 
vs. time for (a) BSA 20–100 and BSA buffer samples; (b) mAb 20 and mAb 50 samples along with mAb buffer. Three (n= 3)
independent samples were analyzed and the error bars represent a standard deviation. We note that buffer solutions also show distinct bi-modal T2
behaviour due to liquid-liquid stratification.
Table IV A Comparison of Average Reconstitution Times from MRI Data
and Visual Observation (n=3)




BSA 20 159a ± 113 90± 20
BSA 50 93a ± 7 140± 50
BSA 75 102a ± 0 220± 60
BSA100 69a ± 30 260± 40
BSA 125 720± 60 1300± 100
BSA 150 1520± 138 2100± 100
mAb 20 32a ± 7 130± 30
mAb 50 202a ± 19 260± 40
mAb 75 600± 158 600± 100
mAb 100 3420± 172 3000± 900
mAb 125 5000b ± 200 6500± 400
mAb 150 6480b,c 10,000± 1000
a
– denotes a reconstitution time from differential, dtavdt
 
, T2 analysis. Note:
error bars for differential T2 analysis were calculated as a standard deviation
(n=3)
b – acquisition time for mAb 125 and 150 was extended to t > 4 h to allow
complete reconstitution
c n=1 for mAb 150 due to limited samples
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the final swirled sample at t =∞ represents a state with no
remaining solids, which we define as 0% and that any differ-
ences in 1H signal intensity are due to remaining undissolved
solids. Crucially, this method does not work when liquid strat-
ification is present, as seen in many low concentration sam-
ples, and is only valid when a reconstituting system has
reached a steady state as indicated by the appearance of the
white bars in Fig. 10. For example, the mAb 75 sample shows
negligible evidence of stratification (see Fig. 5(h)) and has been
determined from morphological analysis to have reached a
steady state at t = 408 ± 30 s. Using the calibration data de-
scribed in the experimental section and supplementary infor-
mation S1-S3 it is possible to estimate the remaining solids
concentration for the mAb 75 sample. The results of this anal-
ysis are shown in Fig. 14 and indicate that at t = 400 s approx-
imately 6% solids remain, with this value decreasing to 0.5%
by t = 3500 s at the end of the experiment, which within ex-
perimental error, indicates that the mAb 75 sample can be
considered as fully reconstituted. Hence, with suitable calibra-
tion of known samples, the 1H signal intensity alone of a ho-
mogeneous steady state reconstitution system can be used to
estimate the remaining solid contents with time.
CONCLUSIONS AND OUTLOOK
MR imaging coupled with an objective analysis of T2 relaxa-
tion time distributions has been applied to two different lyoph-
ilized products: a model BSA system and a mAb sample with
protein concentrations varying from 20 to 150 mg/ml in each
case. A quantitative morphological analysis of 2D 1H RARE
images coupled with partitioning/differential analysis of the
Fig. 13 (a) Spatially resolved protein concentrationmaps post swirling, the color bar has been reversed to indicate that low concentrations would be seen as high
intensity on the MR images in Figs. 4 and 5 and conversely high concentrations would have low intensities in standard 1H imaging. (b) Resulting histogram for a
boxed area (avoiding the meniscus and edges) for mAb 75.
Table V Statistical Analysis of a
Boxed Area (Avoiding Edges and
Meniscus) of the Spatially Resolved
Protein Concentration Maps
Formulation UV Spectroscopy Concentration± SD
(mg/ml)
Average Box Area Concentration± SD
(mg/ml)
BSA 20 20± 2 18.8± 0.5
BSA 50 51± 2 54± 1
BSA 75 79± 3 82± 2
BSA 100 104± 4 104± 2
BSA 125 124± 3 125± 4
BSA 150 159± 8 167± 5
mAb 20 19± 2 18.5± 0.4
mAb 50 49± 2 50.0± 0.8
mAb 75 75± 1 74± 2
mAb 100 105± 1 105± 2
mAb 125 128± 9 119± 2
mAb 150 153± 4 144± 2
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T2 relaxation data gives an objective determination of recon-
stitution times which can be compared with visual analysis.
The results for low concentration BSA protein samples
<100 mg/ml are in reasonable agreement with visual obser-
vation times though large differences are attributed to the
subjective nature of the manual/visual reconstitution method
with regard to undissolved solids. A good agreement is seen
when comparing the reconstitution times from T2 data and
visual observations for mAb samples. MR diffusion imaging
has further revealed that liquid stratification occurs, especially
for low protein concentration samples (e.g. 20–50 mg/ml),
giving rise to two distinct liquid layers with different viscosities
and water self-diffusion coefficients. For BSA and mAb 20
samples, continuous MR imaging for over 14 h showed that
these layers eventually form a homogenous mixture with mass
transfer being limited by molecular self-diffusion processes. At
higher protein concentrations (100–50 mg/ml) for both BSA
and mAb samples, stratification is less apparent. The discov-
ery of liquid stratification prevented a simple (partitioning)
analysis of the T2 data to determine reconstitution times for
certain samples. Despite stratification phenomena, giving long
periods of transitional average T2 behaviour, a differential anal-
ysis of the T2 data was shown to be appropriate in determining
a more realistic reconstitution time. An important consider-
ation in this was the use of morphological analysis of the 2D
1H images to reveal a unique time point at which these systems
can be deemed to have reached a steady state relative to a
reference buffer solution. Quantitative protein concentrations
of the final swirled solutions can be determined from the 1H
MR image intensities as long as MR calibration procedures of
known phantoms are determined under the same experimen-
tal MRI parameters used to image the reconstitution process.
The results from MRI determined protein concentrations are
in excellent agreement with those from standard UV-vis anal-
ysis. At present the MRI protein quantification method only
allows us to determine the protein concentration from a ho-
mogenous 2D image and is thus not applicable to liquid-liquid
stratified systems. This is because the current calibration data
is based upon the addition of a minimum of 1 ml of water and
subsequent dilution thereafter. In order to relate the 1H image
intensity of stratified systems to the absolute protein concen-
tration, further calibration experiments are required where
additional solids are added to a fixed amount of water, e.g.
1 ml. A demonstration of how the magnetic resonance cali-
bration data can also be used to estimate the remaining solids
content of a dissolved homogenous system (e.g. mAb 75 was
shown. Further refinements of the bi-modal T2 behaviour
data from stratified systems is ongoing in an attempt to esti-
mate remaining solids content from stratified systems. Finally,
the 1H single shot CPMG technique for both reconstitution
time and final concentration determination could be translat-
ed to an inexpensive low field instrument, and with further
investigation could become a validated QC test in industry
and clinical settings. Future work will focus on how the mag-
netic resonance imaging and T2 relaxation data described
here can be combined with both in situ porosity measurements
of the lyophilized solid product and solid state NMR studies,
in an attempt to understand the underlying physicochemical
mechanisms governing reconstitution times for lyophilized
drug products with different excipient formulations and pro-
tein concentrations.
OpenAccessThis article is distributed under the terms of the
Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which per-
mits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
REFERENCES
1. FDA. Guideline for the Determination of Residual Moisture in
Dried Biological Products. 1990;(89):[DOCKET NO. 89D-0140].
2. Pikal MJ. Freeze-drying of proteins. Part I: Process design.
BioPharm. 1990;3(8):18–27.
3. Pikal MJ. Freeze-drying of proteins. Part II: Formulation Selection.
BioPharm. 1990;3:26–30.
4. Carpenter JF, PikalMJ, Chang BS, RandolphTW.Rational design
of stable lyophilized protein formulations: some practical advice.
Pharm Res. 1997 Aug;14(8):969–75.
Fig. 14 Plot of the variation in percentage remaining solids content versus
time for mAb 75.
Pharm Res (2019) 36: 71 Page 19 of 21 71
5. Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW.
Rational design of stable lyophilized protein formulations: theory
and practice. Pharm Biotechnol. 2002;13:109–33.
6. Manning MC, Patel K, Borchardt RT. Stability of protein phar-
maceuticals. Pharm Res. 1989;6(11):903–18.
7. Cleland JL, Powell MF, Shire SJ. The development of stable
protein formulations: a close look at protein aggregation,
deamidation, and oxidation. Crit Rev Ther Drug Carrier
Syst. 1993;10(4):307–77.
8. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. Factors
affecting short-term and long-term stabilities of proteins. Adv
Drug Deliv Rev. 2001;46(1):307–26.
9. WangW. Instability, stabilization, and formulation of liquid protein
pharmaceuticals. Int J Pharm. 1999;185(2):129–88.
10. Tang X, Pikal MJ. Design of Freeze-Drying Processes for pharma-
ceuticals: practical advice. Pharm Res. 2004;21(2):191–200.
11. Webb SD, Cleland JL, Carpenter JF, Randolph TW. Effects of
annealing lyophilized and spray-lyophilized formulations of recom-
binant human interferon-gamma. J Pharm Sci. 2003;92(4):715–29.
12. Blue J, Yoder H. Succesful lyophilization development of potein
therapeutics. Am Pharm Rev. 2009;12:90–6.
13. Searles JA, Carpenter JF, Randolph TW. Annealing to optimize
the primary drying rate, reduce freezing-induced drying rate het-
erogeneity, and determine T'g pharmaceutical lyophilization. J
Pharm Sci. 2001;90(7):872–87.
14. Patel SM, Nail SL, Pikal MJ, Geidobler R, Winter G, Hawe A,
et al. Lyophilized drug product cake appearance:what is accept-
able? J Pharm Sci. 2017:1–16.
15. Beech KE, Biddlecombe JG, Van Der Walle CF, Stevens LA,
Rigby SP, Burley JC, et al. Insights into the influence of the cooling
profile on the reconstitution times of amorphous lyophilized protein
formulations. Eur J Pharm Biopharm. 2015;96:247–54.
16. <1> Injections and Implanted Drug Products (Parenterals) -
Product Quality Tests. United States Pharmacop USP. 2016;41(5).
17. <1790> VISUAL INSPECTION OF INJECTIONS. United
States Pharmacop USP. 2016;41(1).
18. Melchore JA, Berdovich D. Considerations for design and
use of container challenge sets for qualification and valida-
tion of visible particulate inspection. PDA J Pharm Sci
Technol. 2012;66(3):273–84.
19. Werk T, Huwyler J, Hafner M, Luemkemann J, Mahler H-C. An
impedance-based method to determine reconstitution time for
freeze-dried pharmaceuticals. J Pharm Sci. 2015;104(9):2948–55.
20. ThiermannH, Schreiner R, Eyer P. Dissolution kinetics of unstable
drugs in two-compartment autoinjectors: analysis of the individual
shaking behaviour and influence of various shaking parameters on
the dissolution rate of HI 6 in an automated system. Int J Pharm.
1998;170(1):23–32.
21. Confalonieri C, Cristina G, Farina M. The use of a new laser
particle sizer and shape analyser to detect and evaluate gelatinous
microparticles suspended in reconstituted anthracycline infusion
solutions. J Pharm Biomed Anal. 1991;9(1):1–8.
22. Hill R, Bogdan G, Dart R. Time to reconstitution: purified fab
antivenom vs. unpurified IgG antivenom. Toxicon. 2001;39.
23. Cao W, Krishnan S, Ricci MS, Shih L-Y, Liu D, Gu JH, et al.
Rational design of lyophilized high concentration protein
formulations-mitigating the challenge of slow reconstitution with
multidisciplinary strategies. Eur J Pharm Biopharm. 2013;85(2):
287–93.
24. Geidobler R, Winter G. Controlled ice nucleation in the field of
freeze-drying: fundamentals and technology review. Eur J Pharm
Biopharm. 2013;85(2):214–22.
25. Awotwe-OtooD, Agarabi C, Read EK, Lute S, Brorson KA,Khan
MA, et al. Impact of controlled ice nucleation on process perfor-
mance and quality attributes of a lyophilized monoclonal antibody.
Int J Pharm. 2013;450(1):70–8.
26. Overcashier DE, Patapoff TW, Hsu CC. Lyophilization of protein
formulations in vials: investigation of the relationship between re-
sistance to vapor flow during primary drying and small-scale prod-
uct collapse. J Pharm Sci. 1999;88(7):688–95.
27. Johnson RE, Oldroyd ME, Ahmed SS, Gieseler H, Lewis LM. Use
of Manometric temperature measurements (MTM) to characterize
the freeze-drying behavior of amorphous protein formulations. J
Pharm Sci. 2010;99(6):2863–73.
28. Krokida MK, Karathanos VT, Maroulis ZB. Effect of freeze-
drying conditions on shrinkage and porosity of dehydrated agricul-
tural products. J Food Eng. 1998;35(4):369–80.
29. Lin LH, Bunnell R. Overcoming Challenges in the
Reconstitution of a High- Concentration Protein Drug
Product. 2013;(March):1–5.
30. Shire SJ, Shahrokh Z, Liu J. Challenges in the development
of high protein concentration formulations. J Pharm Sci.
2004;93:1390–402.
31. Krishnan S, Pallitto M, Nagle S, Crampton SL, Ricci MS, Cao W,
et al. Concentrated protein lyophilates, methods, and uses [inter-
net]. In: Google Patents; 2007.
32. Shire SJ. Formulation and manufacturability of biologics. Curr
Opin Biotechnol. 2009;20(6):708–14.
33. Liao X, Krishnamurthy R, Suryanarayanan R. Influence of the
active pharmaceutical ingredient concentration on the physical
state of mannitol—implications in freeze-drying. Pharm Res.
2005;22(11):1978–85.
34. Cao W, Xie Y, Krishnan S, Lin H, Ricci M. Influence of process
conditions on the crystallization and transition of metastable man-
nitol forms in protein formulations during Lyophilization. Pharm
Res. 2013;30(1):131–9.
35. Mensink MA, Nethercott MJ, Hinrichs WLJ, van der Voort
Maarschalk K, Frijlink HW, Munson EJ, et al. Influence of misci-
bility of protein-sugar Lyophilizates on their storage stability. AAPS
J. 2016 Sep;18(5):1225–32.
36. Duru C, Swann C, Dunleavy U, Mulloy B, Matejtschuk P. The
importance of formulation in the successful lyophilization of influ-
enza reference materials. Biologicals. 2015;43(2):110–6.
37. Lam Y-H, Bustami R, Phan T, Chan H-K, Separovic F. A solid-
state NMR study of protein mobility in lyophilized protein–sugar
powders. J Pharm Sci. 2002;91(4):943–51.
38. Yoshioka S, Aso Y, Kojima S. The effect of excipients on the mo-
lecular mobility of lyophilized formulations, as measured by glass
transition temperature and NMR relaxation-based critical mobility
temperature. Pharm Res. 1999 Jan;16(1):135–40.
39. Rutledge DN, Rene F, Hills BP, Foucat L. Magnetic resonance
imaging studies of the freeze-drying of potato. J Food Process
Eng. 1994;17(3):325–52.
40. Taraban MB, DePaz RA, Lobo B, Yu YB. Water proton NMR: a
tool for protein aggregation characterization. Anal Chem. 2017
May 16;89(10):5494–502.
41. Luthra SA, Pikal MJ, UtzM. Solid state 13C NMR investigation of
impact of annealing in lyophilized glasses. J Pharm Sci. 2008
Oct 1;97(10):4336–46.
42. Yuan X, Sperger D, Munson EJ. Investigating miscibility and mo-
lecular mobility of Nifedipine-PVP amorphous solid dispersions
using solid-state NMR spectroscopy. Mol Pharm. 2014 Jan;11(1):
329–37.
43. Separovic F, Lam YH, Ke X, Chan H-K. A solid-state NMR study
of protein hydration and stability. Pharm Res. 1998 Dec;15(12):
1816–21.
44. Hollingsworth KG, Johns ML. Measurement of emulsion droplet
sizes using PFG NMR and regularization methods. J Colloid
Interface Sci. 2003 Feb 15;258(2):383–9.
45. Mitchell J, Chandrasekera TC,HollandDJ, Gladden LF, Fordham
EJ. Magnetic resonance imaging in laboratory petrophysical core
analysis. Phys Rep. 2013 May 1;526(3):165–225.
71 Page 20 of 21 Pharm Res (2019) 36: 71
46. Venkataramanan L, Song Y-Q, Hurlimann MD. Solving
Fredholm integrals of the first kind with tensor product structure
in 2 and 2.5 dimensions. IEEE Trans Signal Process. 2002;50(5):
1017–26.
47. Mitchell J, Chandrasekera TC, Gladden LF. Numerical estimation
of relaxation and diffusion distributions in two dimensions. Prog
Nucl Magn Reson Spectrosc. 2012;62:34–50.
48. Song Y-Q, Venkataramanan L, Hürlimann MD, Flaum M, Frulla
P, Straley C. T1–T2 correlation spectra obtained using a fast two-
dimensional Laplace inversion. J Magn Reson. 2002 Feb 1;154(2):
261–8.
49. BorgiaGC, BrownRJS, Fantazzini P. Uniform-penalty inversion of
multiexponential decay data. J Magn Reson. 1998 May 1;132(1):
65–77.
50. Song Y-Q, Venkataramanan L, Burcaw L. Determining the reso-
lution of Laplace inversion spectrum. J Chem Phys. 2005 Mar
8;122(10):104104.
51. Kroeker RM, Mark Henkelman R. Analysis of biological NMR
relaxation data with continuous distributions of relaxation times. J
Magn Reson. 1986 Sep 1;69(2):218–35.
52. Koskela H, Kilpeläinen I, Heikkinen S. Evaluation of protein 15N
relaxation times by inverse Laplace transformation. Magn Reson
Chem. 2004 Jan 1;42(1):61–5.
53. Mitchell J, Chandrasekera TC, Gladden LF. A general approach to
T2 measurements in the presence of internal gradients.
Microporous Mesoporous Mater. 2013 Sep 15;178:20–2.
54. Baughman JA, Joseph Ray G, Christina SM, Werling JO, Rinaldi
PL. 1H NMR study of the phase behavior of aqueous eutectic
solutions using the inverse Laplace transform analysis of T2 relax-
ation. Magn Reson Chem. 2017 Oct 1;55(10):928–35.
55. Chen YY, Hughes LP, Gladden LF, Mantle MD. Quantitative
ultra-fast MRI of HPMC swelling and dissolution. J Pharm Sci.
2010 Aug 1;99(8):3462–72.
56. Callaghan PT. Principles of nuclear magnetic resonance microsco-
py. Oxford: Clarendon Press; 1993.
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional
claims in published maps and institutional affiliations.
Pharm Res (2019) 36: 71 Page 21 of 21 71
